- Conditions
- Clostridium Infections
- Interventions
- GS-CDA1/MDX-1388, normal saline
- Biological
- Lead sponsor
- MassBiologics
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 22
- States / cities
- Los Angeles, California • Oakland, California • Newark, Delaware + 18 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 796
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cystic Fibrosis
- Interventions
- Throat Swab
- Procedure
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 1 Day to 3 Months
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Anthrax
- Interventions
- AV7909, BioThrax
- Biological
- Lead sponsor
- Emergent BioSolutions
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 168 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 4
- States / cities
- Miami, Florida • Mt. Pleasant, South Carolina • New Braunfels, Texas + 1 more
- Conditions
- Tuberculosis
- Interventions
- Moxifloxacin, Isoniazid
- Drug
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2007
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Baltimore, Maryland • Durham, North Carolina + 3 more
- Conditions
- Pneumococcal Infections
- Interventions
- Prevnar 13, multivalent pneumococcal conjugate formulation 1, multivalent pneumococcal conjugate formulation 2
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 4
- States / cities
- Garden Grove, California • Long Beach, California • Honolulu, Hawaii + 1 more
- Conditions
- Staphylococcal Aureus Infection, Recurrent Staphylococcal Infection, Invasive Staphylococcal Infection
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Clostridium Infections
- Interventions
- Not listed
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 7
- States / cities
- Sacramento, California • Hamden, Connecticut • Boston, Massachusetts + 3 more
- Conditions
- Clostridium Difficile Colitis
- Interventions
- fecal microbiota
- Biological
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Acquired Immunodeficiency Syndrome, Mycobacterium Avium-Intracellulare Infection
- Interventions
- Interleukin-12
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- HIV Infections
- Interventions
- Thalidomide
- Drug
- Lead sponsor
- Rockefeller University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Tuberculosis
- Interventions
- Nucleic Acid Amplification Methods for diagnosis
- Other
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 10
- States / cities
- Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 7 more
- Conditions
- HIV Infections, Tuberculosis
- Interventions
- Nelfinavir mesylate, Ethambutol hydrochloride, Isoniazid, Pyrazinamide, Lamivudine, Rifabutin, Stavudine, Zidovudine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 10
- States / cities
- Los Angeles, California • San Diego, California • Chicago, Illinois + 4 more
- Conditions
- Pneumococcal Infections
- Interventions
- V114, Prevnar 13™, PNEUMOVAX™23
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 1,515 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 38
- States / cities
- Chinle, Arizona • Fort Defiance, Arizona • Glendale, Arizona + 34 more
- Conditions
- Mycobacterium Avium-intracellulare Infection, HIV Infections
- Interventions
- Clarithromycin
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Chicago, Illinois • Baltimore, Maryland
- Conditions
- Mycobacterium Avium-Intracellulare Infection, HIV Infections
- Interventions
- Nelfinavir mesylate
- Drug
- Lead sponsor
- Agouron Pharmaceuticals
- Industry
- Eligibility
- 13 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 5
- States / cities
- San Diego, California • Torrance, California • Chicago, Illinois + 2 more
- Conditions
- Pneumococcal Disease
- Interventions
- V116, Placebo, PCV15, PPSV23, PCV15 - Part B
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Washington D.C., District of Columbia • Ft. Pierce, Florida + 4 more
- Conditions
- Treponema Pallidum, Treponema Pallidum Infection, Syphilis Infection, Serum, Plasma, Blooddraw, Sexually Transmitted Infection (STI)
- Interventions
- ALPCO Syphilis-T, ALPCO Syphilis-NT CLIA Kits
- Device
- Lead sponsor
- American Laboratory Products Company
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 6
- States / cities
- Lancaster, California • Los Angeles, California • North Miami, Florida + 3 more
- Conditions
- Pneumococcal Infection
- Interventions
- V116, PPSV23
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 882 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Madera, California + 23 more
- Conditions
- Clostridium Difficile Infection
- Interventions
- Microbiota Enrichment Program (MEP)
- Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Decatur, Georgia
- Conditions
- Healthy
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1980 – 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Gram-Positive Infections
- Interventions
- IV Tedizolid Phosphate, Oral Suspension Tedizolid Phosphate
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 1 Day to 24 Months
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 7
- States / cities
- Little Rock, Arkansas • Orange, California • San Diego, California + 4 more
- Conditions
- Inflammatory Bowel Diseases, Clostridioides Difficile Infection
- Interventions
- Xylitol, Placebo
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2033
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Inflammatory Bowel Diseases, Clostridium Difficile Infection
- Interventions
- Fecal Microbiota Transplantation
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Congenital Heart Diseases, Aortic Valve Disorder
- Interventions
- Cefazolin 25 mg/kg body weight and Vancomycin hydrochloride, Cefazolin 30 mg/kg body weight
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Palo Alto, California